Developer docs
API playgroundTry for free, no card

Search company profiles

Umedeor

Full company profile

uuid0000y9g

Namestring
Umedeor
Legal namestring
uMed Technologies Inc.
Websiteurl
umed.io
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial recruitment, real-world evidence, patient cohort platform, decentralized clinical trials, electronic health records
Industry2 codes
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGACAH
Decentralized & Hybrid Trial Site Services (Home Health/Nursing)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Clinical Research Technology
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Research Services
TypeProfessional Services
Description

uMed provides modular study services including recruitment, data collection, sampling, and study management for pharmaceutical sponsors, CROs, and research institutions. Revenue is generated through service contracts for clinical trials and observational studies.

umed.io
2Cohort Access Subscriptions
TypeSubscription Recurring
Description

ACCESS Cohorts provide reusable, scalable research resources. Sponsors and researchers pay for access to prospectively recruited patient populations linked to EHR data for evidence generation across drug development lifecycle stages.

umed.io
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom enterprise pricing based on study requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies based on study type (observational vs interventional), number of patients, service modules selected (Recruit, Collect, or combined), data collection depth, and geographic scope. Quote-based sales motion with no public pricing page.

umed.io
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1AccessCMD
Description

Next-generation cardiometabolic research cohort - disease-specific registry embedded within ACCESS research-ready infrastructure for cardiometabolic disease studies.

umed.io
+6 more records
Core offering1 text field

Umedeor (uMed) operates an AI-driven clinical research platform that combines electronic health record (EHR) integration with pre-consented patient cohorts to enable decentralized clinical trials and real-world evidence generation for pharmaceutical sponsors, contract research organizations (CROs), and academic research institutions. The platform supports the full drug development lifecycle through modular study services including patient recruitment, decentralized data collection, and longitudinal cohort studies across disease-specific registries for cardiometabolic disease, Parkinson's disease, and interstitial lung disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 6,500 patient responses collected in 5 days for GLP-1 survey
+8 more records
Product overview1 text field

uMed is a clinical research technology company offering a platform-plus-modules architecture for evidence generation in clinical trials and real-world research. The core offering is the ACCESS Cohorts platform (with SpanACCESS for longitudinal evidence and SnapACCESS for rapid qualitative insights), supported by Study Services modules (Collect for decentralized data collection and Recruit for patient recruitment). Disease-specific research platforms include ACCESSCMD (cardiometabolic), ACCESSPD (Parkinson's disease), and ACCESSILD (interstitial lung disease). The platform links consented patients with their routine care data via EHR integration and enables remote engagement for decentralized clinical research.

Product and service8 records
1ACCESS Cohorts
CategoryCore platform
Description

Prospectively recruited, EMR-linked registries that follow real patients over time. Built to be reusable, scalable living research resources linking consented patients with their routine care data and enabling remote engagement for faster, more representative evidence generation. Designed for pharmaceutical sponsors, CROs, and research institutions needing longitudinal real-world data.

2SpanACCESS
CategoryCohort module
Description

Flexible, longitudinal engine for real-world evidence generation. Enables customizable, real-world studies using pre-consented, EMR-linked patient cohorts with multi-timepoint data capture (baseline, 3, 6, 12+ months) for clinical strategy, regulatory submission, and post-market evidence.

3SnapACCESS
CategoryCohort module
Description

Rapid qualitative research solution bridging patient voice and clinical reality. Delivers verified patient cohorts linked to EHR data with integrated qualitative feedback and real-time insights in under 4 weeks, combining traditional qualitative research speed with clinical validation.

4ACCESSCMD
CategoryDisease-specific cohort platform
Description

Cardiometabolic disease cohort embedded within the ACCESS research infrastructure. Identifies and invites eligible individuals receiving routine care via secure EHR integration. Links longitudinal clinical data with patient-reported outcomes and home-collected biomarker or genetic data across US and UK.

5ACCESSPD
CategoryDisease-specific cohort platform
Description

Next-generation, remote Parkinson's disease registry. Uses electronic health record data to identify and invite patients with confirmed diagnosis across US and UK. Links routine clinical data with ongoing patient-reported outcomes and genetic or biomarker data collected from home.

6ACCESSILD
CategoryDisease-specific cohort platform
Description

Next-generation interstitial lung disease registry. Uses EHR data to identify and invite patients with confirmed diagnosis across US and UK. Links routine clinical data with patient-reported outcomes and genetic or biomarker data collected from home for inclusive research and patient stratification.

7uMed Collect
CategoryStudy service module
Description

Decentralized, longitudinal data collection service. Supports patient-centric trials with remote bio-sampling, smart data collection (ePRO, EHR, primary and secondary care data), patient support hub, and decentralized trial services. Modular system configured per trial needs.

8uMed Recruit
Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Cera
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Partnership to bring clinical research to the point of care, expanding trial recruitment to a long-underserved 65+ cohort. Cera's care delivery platform enables identification of eligible older patients for research opportunities.

umed.io
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-16
Description

Strategic partnership to expand patient access to national clinical research registries, focusing initially on cardiometabolic and Parkinson's disease cohorts in 2026 with plans to include additional therapeutic areas. WellSky provides EHR network infrastructure enabling uMed to identify eligible home care patients for remote research participation.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-11-18
Description

Partnership to drive data-driven market access success in cardiometabolic and Parkinson's disease research. Decisive Consulting provides market access expertise complementary to uMed's patient data capabilities.

4Global Parkinson's Genetics Program (GP2)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-18
Description

Partnership to address emerging research demands in Parkinson's disease through integrated genetic research capabilities. uMed provides patient cohort access and data collection supporting GP2's global genetics initiative.

umed.io
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-20
Description

Partnership for Parkinson's disease research, supporting the PPMI study. Deploys physical smell test kits to patients and facilitates patient referrals to research sites. Over 1,200 kits deployed and 400 patients referred.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-09-08
Description

Partnership with UK's largest health research programme to support population health research initiatives and expand patient recruitment capabilities.

7MCI Onehealth
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2023-03-10
Description

Partnership to accelerate clinical research in Canada by expanding uMed's North American presence and leveraging MCI Onehealth's healthcare network.

umed.io
Strategic tierCoreTypeTechnology or Integration
Description

Accredited partner status with EMIS Health, a leading UK electronic health record provider. Partnership enables secure integration with primary care EHR systems for patient identification and data linkage.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Pharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Pharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Pharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partner listed among key institutions collaborating with uMed for clinical research initiatives.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partner listed among key institutions collaborating with uMed for clinical research initiatives.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partner collaborating on PREDICT-PD and other Parkinson's disease research studies. Prof. Alastair Noyce serves on uMed's Advisory Board.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

Contract research organization partner listed among key collaborators for clinical trial support services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Industry-leading clinical trial technology platform offering EDC, eCOA, randomization, and trial management. Comparable as the dominant incumbent in clinical trial data infrastructure that uMed's ePRO and EHR-linked cohort capabilities must integrate with or differentiate against.

TypeDirect peer
Description

Global real-world evidence and clinical trial recruitment platform built on EHR-linked patient data from health systems. Directly comparable to uMed in using EHR data to identify eligible patients, accelerate trial recruitment, and generate evidence for pharma sponsors.

TypeDirect peer
Description

Cloud-based clinical trial data capture platform with ePRO/eCRF capabilities and decentralized trial support. Comparable as a tech-enabled clinical research platform targeting faster, more efficient study delivery for academic and commercial sponsors.

TypeDirect peer
Description

Clinical trial recruitment and site performance platform (StudyTeam, Care Access). Directly comparable to uMed Recruit as an enterprise platform focused on accelerating patient identification, enrollment, and trial site coordination.

TypeDirect peer
Description

Decentralized clinical trial platform offering remote patient data collection, ePRO, and virtual site operations. Comparable to uMed's decentralized trial capabilities (uMed Collect, ACCESS Cohorts) with overlapping technology stack.

TypeDirect peer
Description

Decentralized clinical trial technology platform supporting eCOA, ePRO, remote consent, and telehealth-based study visits. Directly comparable to uMed's decentralized study services and remote data collection infrastructure.

7Deep 6 AI
TypeDirect peer
Description

AI-powered patient matching platform that mines EHR data to accelerate clinical trial recruitment. Directly comparable to uMed's AI-driven patient identification and EHR-matching capabilities for clinical trial enrollment.

8Mendel
TypeEmerging player
Description

AI platform for clinical trial patient matching and real-world evidence generation using structured and unstructured EHR data. Comparable emerging player using AI to identify eligible patients and accelerate trial recruitment in the same category as uMed Recruit.

TypeBroad incumbent
Description

World's largest CRO with comprehensive clinical research services, real-world evidence, and patient recruitment capabilities. Broad incumbent comparable to uMed's full-service study offering plus RWE platform; competes for the same enterprise sponsor relationships.

TypeBroad incumbent
Description

Alphabet-owned health technology company with clinical research platforms including decentralized trials and real-world evidence tools. Comparable as a well-capitalized incumbent building EHR-integrated research infrastructure that overlaps with uMed's value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers22 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Umedeor

Clinical Research Technologyumed.io

Umedeor firmographics

Firmographics
Name
Umedeor
Legal name
uMed Technologies Inc.
Website
https://umed.io
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Umedeor industry classification

Industry
Product category
Clinical Research Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGACAH
Decentralized & Hybrid Trial Site Services (Home Health/Nursing)

Keywords

  • Clinical trial recruitment
  • Real-world evidence
  • Patient cohort platform
  • Decentralized clinical trials
  • Electronic health records

Where Umedeor is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Umedeor business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Research Services: uMed provides modular study services including recruitment, data collection, sampling, and study management for pharmaceutical sponsors, CROs, and research institutions. Revenue is generated through service contracts for clinical trials and observational studies.
  2. Cohort Access Subscriptions: ACCESS Cohorts provide reusable, scalable research resources. Sponsors and researchers pay for access to prospectively recruited patient populations linked to EHR data for evidence generation across drug development lifecycle stages.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom enterprise pricing based on study requirements

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Umedeor product offering

Product offering

Core offering

Umedeor (uMed) operates an AI-driven clinical research platform that combines electronic health record (EHR) integration with pre-consented patient cohorts to enable decentralized clinical trials and real-world evidence generation for pharmaceutical sponsors, contract research organizations (CROs), and academic research institutions. The platform supports the full drug development lifecycle through modular study services including patient recruitment, decentralized data collection, and longitudinal cohort studies across disease-specific registries for cardiometabolic disease, Parkinson's disease, and interstitial lung disease.

Product overview

uMed is a clinical research technology company offering a platform-plus-modules architecture for evidence generation in clinical trials and real-world research. The core offering is the ACCESS Cohorts platform (with SpanACCESS for longitudinal evidence and SnapACCESS for rapid qualitative insights), supported by Study Services modules (Collect for decentralized data collection and Recruit for patient recruitment). Disease-specific research platforms include ACCESSCMD (cardiometabolic), ACCESSPD (Parkinson's disease), and ACCESSILD (interstitial lung disease). The platform links consented patients with their routine care data via EHR integration and enables remote engagement for decentralized clinical research.

Differentiator

Problem solved

Functional benefit

Brands

  • AccessCMD: Next-generation cardiometabolic research cohort - disease-specific registry embedded within ACCESS research-ready infrastructure for cardiometabolic disease studies.
  • AccessPD
  • AccessILD
  • ACCESS Cohorts
  • SpanACCESS
  • SnapACCESS
  • ACCESS Platform

Products and services

  • ACCESS Cohorts Prospectively recruited, EMR-linked registries that follow real patients over time. Built to be reusable, scalable living research resources linking consented patients with their routine care data and enabling remote engagement for faster, more representative evidence generation. Designed for pharmaceutical sponsors, CROs, and research institutions needing longitudinal real-world data.
  • SpanACCESS Flexible, longitudinal engine for real-world evidence generation. Enables customizable, real-world studies using pre-consented, EMR-linked patient cohorts with multi-timepoint data capture (baseline, 3, 6, 12+ months) for clinical strategy, regulatory submission, and post-market evidence.
  • SnapACCESS Rapid qualitative research solution bridging patient voice and clinical reality. Delivers verified patient cohorts linked to EHR data with integrated qualitative feedback and real-time insights in under 4 weeks, combining traditional qualitative research speed with clinical validation.
  • ACCESSCMD Cardiometabolic disease cohort embedded within the ACCESS research infrastructure. Identifies and invites eligible individuals receiving routine care via secure EHR integration. Links longitudinal clinical data with patient-reported outcomes and home-collected biomarker or genetic data across US and UK.
  • ACCESSPD Next-generation, remote Parkinson's disease registry. Uses electronic health record data to identify and invite patients with confirmed diagnosis across US and UK. Links routine clinical data with ongoing patient-reported outcomes and genetic or biomarker data collected from home.
  • ACCESSILD Next-generation interstitial lung disease registry. Uses EHR data to identify and invite patients with confirmed diagnosis across US and UK. Links routine clinical data with patient-reported outcomes and genetic or biomarker data collected from home for inclusive research and patient stratification.
  • uMed Collect Decentralized, longitudinal data collection service. Supports patient-centric trials with remote bio-sampling, smart data collection (ePRO, EHR, primary and secondary care data), patient support hub, and decentralized trial services. Modular system configured per trial needs.
  • uMed Recruit

Quantifiable outcome

  • 6,500 patient responses collected in 5 days for GLP-1 survey
  • +8 more outcomes

Companies that use Umedeor

Customer profile

Named customers22 records

Segments1 record

Ideal customer profiles2 records

Umedeor technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Umedeor partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and supporting.

  • CeracoreStrategic or Co-development Partner · 11 May 2026Partnership to bring clinical research to the point of care, expanding trial recruitment to a long-underserved 65+ cohort. Cera's care delivery platform enables identification of eligible older patients for research opportunities.
  • WellSkycoreTechnology or Integration · 16 December 2025Strategic partnership to expand patient access to national clinical research registries, focusing initially on cardiometabolic and Parkinson's disease cohorts in 2026 with plans to include additional therapeutic areas. WellSky provides EHR network infrastructure enabling uMed to identify eligible home care patients for remote research participation.
  • Decisive ConsultingsupportingStrategic or Co-development Partner · 18 November 2024Partnership to drive data-driven market access success in cardiometabolic and Parkinson's disease research. Decisive Consulting provides market access expertise complementary to uMed's patient data capabilities.
  • Global Parkinson's Genetics Program (GP2)coreStrategic or Co-development Partner · 18 June 2024Partnership to address emerging research demands in Parkinson's disease through integrated genetic research capabilities. uMed provides patient cohort access and data collection supporting GP2's global genetics initiative.
  • Michael J. Fox FoundationcoreStrategic or Co-development Partner · 20 September 2023Partnership for Parkinson's disease research, supporting the PPMI study. Deploys physical smell test kits to patients and facilitates patient referrals to research sites. Over 1,200 kits deployed and 400 patients referred.
  • Our Future HealthsupportingStrategic or Co-development Partner · 8 September 2023Partnership with UK's largest health research programme to support population health research initiatives and expand patient recruitment capabilities.
  • MCI OnehealthsupportingStrategic or Co-development Partner · 10 March 2023Partnership to accelerate clinical research in Canada by expanding uMed's North American presence and leveraging MCI Onehealth's healthcare network.
  • EMIS HealthcoreTechnology or IntegrationAccredited partner status with EMIS Health, a leading UK electronic health record provider. Partnership enables secure integration with primary care EHR systems for patient identification and data linkage.
  • AstraZenecasupportingStrategic or Co-development PartnerPharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.
  • SanofisupportingStrategic or Co-development PartnerPharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.
  • ModernasupportingStrategic or Co-development PartnerPharmaceutical partner listed among key institutions collaborating with uMed for clinical research initiatives.
  • King's College LondonsupportingStrategic or Co-development PartnerAcademic research partner listed among key institutions collaborating with uMed for clinical research initiatives.
  • University of OxfordsupportingStrategic or Co-development PartnerAcademic research partner listed among key institutions collaborating with uMed for clinical research initiatives.
  • Queen Mary University of LondonsupportingStrategic or Co-development PartnerAcademic research partner collaborating on PREDICT-PD and other Parkinson's disease research studies. Prof. Alastair Noyce serves on uMed's Advisory Board.
  • FortreasupportingChannel Partner/ Reseller/ DistributorContract research organization partner listed among key collaborators for clinical trial support services.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Umedeor competitors and assessment

Company assessment

Broad incumbents

  • Medidata (Dassault Systèmes): Industry-leading clinical trial technology platform offering EDC, eCOA, randomization, and trial management. Comparable as the dominant incumbent in clinical trial data infrastructure that uMed's ePRO and EHR-linked cohort capabilities must integrate with or differentiate against.
  • IQVIA: World's largest CRO with comprehensive clinical research services, real-world evidence, and patient recruitment capabilities. Broad incumbent comparable to uMed's full-service study offering plus RWE platform; competes for the same enterprise sponsor relationships.
  • Verily (Alphabet): Alphabet-owned health technology company with clinical research platforms including decentralized trials and real-world evidence tools. Comparable as a well-capitalized incumbent building EHR-integrated research infrastructure that overlaps with uMed's value proposition.

Direct peers

  • TriNetX: Global real-world evidence and clinical trial recruitment platform built on EHR-linked patient data from health systems. Directly comparable to uMed in using EHR data to identify eligible patients, accelerate trial recruitment, and generate evidence for pharma sponsors.
  • Castor: Cloud-based clinical trial data capture platform with ePRO/eCRF capabilities and decentralized trial support. Comparable as a tech-enabled clinical research platform targeting faster, more efficient study delivery for academic and commercial sponsors.
  • Reify Health: Clinical trial recruitment and site performance platform (StudyTeam, Care Access). Directly comparable to uMed Recruit as an enterprise platform focused on accelerating patient identification, enrollment, and trial site coordination.
  • ObvioHealth: Decentralized clinical trial platform offering remote patient data collection, ePRO, and virtual site operations. Comparable to uMed's decentralized trial capabilities (uMed Collect, ACCESS Cohorts) with overlapping technology stack.
  • THREAD: Decentralized clinical trial technology platform supporting eCOA, ePRO, remote consent, and telehealth-based study visits. Directly comparable to uMed's decentralized study services and remote data collection infrastructure.
  • Deep 6 AI: AI-powered patient matching platform that mines EHR data to accelerate clinical trial recruitment. Directly comparable to uMed's AI-driven patient identification and EHR-matching capabilities for clinical trial enrollment.

Emerging players

  • Mendel: AI platform for clinical trial patient matching and real-world evidence generation using structured and unstructured EHR data. Comparable emerging player using AI to identify eligible patients and accelerate trial recruitment in the same category as uMed Recruit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Umedeor social profiles

Digital presence

Umedeor compliance and trust

Trust signal

Compliance6 records

Umedeor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Umedeor leadership team

Management profile

Number of profiles

Profiles11 records

Umedeor subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Umedeor funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Umedeor M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Umedeor

What does Umedeor do?

Umedeor (uMed) operates an AI-driven clinical research platform that combines electronic health record (EHR) integration with pre-consented patient cohorts to enable decentralized clinical trials and real-world evidence generation for pharmaceutical sponsors, contract research organizations (CROs), and academic research institutions. The platform supports the full drug development lifecycle through modular study services including patient recruitment, decentralized data collection, and longitudinal cohort studies across disease-specific registries for cardiometabolic disease, Parkinson's disease, and interstitial lung disease.

Is Umedeor a public or private company?

Umedeor is a private company. It is classified as venture growth investor backed and is currently operating.

When was Umedeor founded?

Umedeor was founded in 2021. It employs 51 to 100 people.

Where is Umedeor based?

Umedeor is headquartered in London, United Kingdom, in the Europe region.

How does Umedeor make money?

Two revenue lines are on record. Clinical Research Services are the primary driver. The others are cohort Access Subscriptions.

Who are Umedeor's main competitors?

Broad incumbents on record are Medidata (Dassault Systèmes), IQVIA and Verily (Alphabet). Direct peers are TriNetX, Castor, Reify Health, ObvioHealth, THREAD and Deep 6 AI. Mendel is listed as an emerging player.

Does Umedeor have an API?

No public API is recorded for Umedeor.

What industry is Umedeor in?

Umedeor's product category is Clinical Research Technology. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLAGACAH, Decentralized & Hybrid Trial Site Services (Home Health/Nursing). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals